Related Experiment Video
Updated: Jun 27, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
AI-Driven Discovery of Prototype CLEC4M Inhibitors Targeting Marburg Virus Entry via Integrated Machine Learning and
Mohammed Almaghrabi1, Mansour S Alturki2
1Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Al Madinah 30001, Saudi Arabia.
Abstract:
Marburg virus (MARV), a highly pathogenic member of the Filoviridae family, causes severe hemorrhagic fever with a high case fatality rate and currently lacks effective therapeutics. The viral entry process, mediated by the interaction between the MARV glycoprotein (GP) and host receptor C-type lectin domain family 4 member M (CLEC4M) (L-SIGN), represents a critical target for early-stage intervention. The active compounds from BindingDB and the decoy from DUDE were used. The RDKit was used for feature engineering. Machine learning models were trained on an initial dataset consisting of 56 active chemicals and 1232 decoys. Among the tested algorithms, the Random Forest model demonstrated superior performance, achieving the highest discriminative ability (AUC = 0.93, MCC = 0.88) on the test set. Virtual screening of 11,032 phytochemicals resulted in 120 predicted actives, of which 42 compounds satisfied drug-likeness criteria. Subsequent molecular docking identified three lead compounds (PubChem IDs: 42608095, 5281601, and 11243993) with moderate-to-promising binding affinities (-6.3 to -6.5 kcal/mol) toward the CLEC4M binding site. ADMET analysis revealed favorable pharmacokinetic and toxicity profiles for the selected lead compounds. DFT calculations of the three compounds highlighted their electronic stability and reactive nature, indicating that PubChem IDs 42608095 and 5281601 possess particularly stable electronic properties conducive to favorable target interactions. Combining machine learning models with molecular docking and Molecular Dynamics (MD) simulations worked well in finding promising phytochemical inhibitors. The MM/GBSA binding free energy calculations further confirmed binding affinities, with values of -10.83 and -11.08 kcal/mol, respectively, suggesting favorable complex stability. These findings provide a pathway for developing new antiviral agents against MARV, pending further experimental validation and optimization.
Insights
Researchers identified potential phytochemical inhibitors for Marburg virus (MARV) by combining machine learning and molecular docking. This approach offers a promising strategy for developing new antiviral therapies against MARV infection.
Area of Science:
- Virology
- Computational Chemistry
- Drug Discovery
Background:
- Marburg virus (MARV) causes severe hemorrhagic fever with high mortality.
- Effective therapeutics for MARV are currently unavailable.
- MARV glycoprotein (GP) interaction with host receptor CLEC4M (L-SIGN) is a key target for intervention.
Purpose of the Study:
- To identify novel phytochemical inhibitors targeting the MARV-CLEC4M interaction.
- To utilize machine learning and molecular modeling for drug discovery.
Main Methods:
- Machine learning models (Random Forest) were trained and validated using chemical databases.
- Virtual screening of 11,032 phytochemicals was performed.
- Molecular docking, ADMET analysis, DFT, and MD simulations were employed to evaluate lead compounds.
Main Results:
- A Random Forest model achieved high performance (AUC=0.93, MCC=0.88).
- Virtual screening identified 120 potential active compounds, with 42 meeting drug-likeness criteria.
- Three lead compounds (PubChem IDs: 42608095, 5281601, 11243993) showed promising binding affinities and favorable ADMET profiles.
Conclusions:
- The study successfully identified potential phytochemical inhibitors for MARV entry.
- Combining computational methods is effective for discovering antiviral agents.
- Further experimental validation is needed to develop new MARV therapeutics.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release
Drug Discovery: Overview
Inhibitors of Viral Protein Synthesis

